Literature DB >> 32157642

Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient.

Rosa Maria Bruno1,2, Stefano Taddei3, Claudio Borghi4, Furio Colivicchi5, Giovambattista Desideri6, Guido Grassi7, Alberto Mazza8, Maria Lorenza Muiesan9, Gianfranco Parati10,11, Roberto Pontremoli12, Bruno Trimarco13, Massimo Volpe14,15, Claudio Ferri6.   

Abstract

Renal denervation is a device-based procedure for hypertension for which safety and efficacy has been demonstrated. At present, its clinical use is still matter of debate, despite the most recent clinical trials have shown promising results with new-generation devices in various hypertensive populations. This position paper was deemed necessary by the Italian Society of Arterial Hypertension, in order to provide indications about the applications of renal denervation in the clinical setting. A state-of-the art review of the literature, focusing on safety and efficacy data, is provided. Furthermore, based on current evidence and expert consensus, clinical profiles of possible candidates for renal denervation are proposed. The selection process should take into account not only blood pressure values, global cardiovascular risk profile, but also drug adherence and tolerability and patient preferences. This position paper also defines minimum requirements for renal denervation selection centers and a flowchart for the difficult-to-treat hypertensive patient. Further studies are needed to support these preliminary indications, which are based on expert-consensus only.

Entities:  

Keywords:  Adherence; Hypertension; Patient preferences; Patient selection; Renal denervation

Mesh:

Substances:

Year:  2020        PMID: 32157642     DOI: 10.1007/s40292-020-00367-0

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  63 in total

1.  Renal Denervation in the Management of Hypertension: A Meta-Analysis of Sham-Controlled Trials.

Authors:  Khagendra Dahal; Maria Khan; Najam Siddiqui; George Mina; Pavan Katikaneni; Kalgi Modi; Michael Azrin; Juyong Lee
Journal:  Cardiovasc Revasc Med       Date:  2019-07-26

2.  Renal artery denervation for treating resistant hypertension : definition of the disease, patient selection and description of the procedure.

Authors:  Massimo Volpe; Enrico Agabiti Rosei; Ettore Ambrosioni; Santina Cottone; Cesare Cuspidi; Claudio Borghi; Nicola De Luca; Francesco Fallo; Claudio Ferri; Giuseppe Mancia; Alberto Morganti; Maria Lorenza Muiesan; Riccardo Sarzani; Leonardo Sechi; Giuliano Tocci; Agostino Virdis
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-02-19

3.  Renal denervation: a blunt weapon against isolated systolic hypertension?

Authors:  Rosa Maria Bruno; Stefano Taddei
Journal:  Eur Heart J       Date:  2017-01-07       Impact factor: 29.983

Review 4.  Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension.

Authors:  Elena Berra; Michel Azizi; Arnaud Capron; Aud Høieggen; Franco Rabbia; Sverre E Kjeldsen; Jan A Staessen; Pierre Wallemacq; Alexandre Persu
Journal:  Hypertension       Date:  2016-06-13       Impact factor: 10.190

5.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.

Authors:  David E Kandzari; Deepak L Bhatt; Sandeep Brar; Chandan M Devireddy; Murray Esler; Martin Fahy; John M Flack; Barry T Katzen; Janice Lea; David P Lee; Martin B Leon; Adrian Ma; Joseph Massaro; Laura Mauri; Suzanne Oparil; William W O'Neill; Manesh R Patel; Krishna Rocha-Singh; Paul A Sobotka; Laura Svetkey; Raymond R Townsend; George L Bakris
Journal:  Eur Heart J       Date:  2014-11-16       Impact factor: 29.983

Review 6.  Secondary arterial hypertension: when, who, and how to screen?

Authors:  Stefano F Rimoldi; Urs Scherrer; Franz H Messerli
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

7.  Five-year blood pressure control and mortality following health education for hypertensive patients.

Authors:  D E Morisky; D M Levine; L W Green; S Shapiro; R P Russell; C R Smith
Journal:  Am J Public Health       Date:  1983-02       Impact factor: 9.308

8.  Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension.

Authors:  Mustafa Ezzahti; Adriaan Moelker; Edith C H Friesema; Nicole A J van der Linde; Gabriel P Krestin; Anton H van den Meiracker
Journal:  J Hypertens       Date:  2014-01       Impact factor: 4.844

9.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

10.  Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.

Authors:  Felix Mahfoud; George Bakris; Deepak L Bhatt; Murray Esler; Sebastian Ewen; Martin Fahy; David Kandzari; Kazuomi Kario; Giuseppe Mancia; Michael Weber; Michael Böhm
Journal:  Eur Heart J       Date:  2017-01-07       Impact factor: 29.983

View more
  6 in total

Review 1.  [Renal denervation : Really an alternative to reducing blood pressure?]

Authors:  Kristina Striepe; Mario Schiffer; Roland Schmieder
Journal:  Internist (Berl)       Date:  2022-01-14       Impact factor: 0.743

2.  Renal Denervation in Daily Practice: If So, How?

Authors:  Dominic Millenaar; Insa Emrich; Felix Mahfoud
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-04-23

3.  TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice.

Authors:  Krzysztof J Filipiak; Miguel Camafort Babkowski; Matteo Cameli; Stefano Carugo; Claudio Ferri; Djamshid B Irisov; Krzysztof Narkiewicz; Ulugbek Nizamov; Leopoldo Pérez de Isla; Anna Tomaszuk-Kazberuk; Andrea Ungar; Aleksandra Gąsecka
Journal:  Cardiol J       Date:  2022-09-19       Impact factor: 3.487

Review 4.  Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases.

Authors:  Le Li; Zhao Hu; Yulong Xiong; Yan Yao
Journal:  Front Cardiovasc Med       Date:  2021-12-09

Review 5.  Advances in the Treatment Strategies in Hypertension: Present and Future.

Authors:  Paolo Verdecchia; Claudio Cavallini; Fabio Angeli
Journal:  J Cardiovasc Dev Dis       Date:  2022-03-03

6.  Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension.

Authors:  Roland E Schmieder; David E Kandzari; Tzung-Dau Wang; Ying-Hsiang Lee; Gabriel Lazarus; Atul Pathak
Journal:  J Hypertens       Date:  2021-01       Impact factor: 4.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.